文献速递瓣膜病与结构性心脏病

复发性心包炎的影像学与靶向治疗进展:综述

Advances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review.
PubMed 文献 · JAMA Cardiol · 2022-01-01

复发性心包炎影响15%至30%的初发心包炎患者,首次复发后高达50%的患者会再次复发,常进展为秋水仙碱抵抗和皮质类固醇依赖。该叙述性综述检索PubMed和Cochrane数据库至2022年4月的文献,总结心脏磁共振成像在诊断、风险分层和管理中的作用,以及白细胞介素-1阻滞剂在复发性心包炎中的疗效证据。

要点

  • 复发性心包炎影响15%至30%的初发患者,首次复发后高达50%会再复发。
  • 新型临床试验和注册数据显示白细胞介素-1阻滞剂对复发性心包炎有效。
  • 新观察数据支持心脏磁共振用于诊断、风险分层和管理。

核心结论

  • 影像学和靶向治疗的进展已使复发性心包炎的管理发生范式转变。

研究设计与样本

  • 叙述性综述,检索PubMed和Cochrane数据库中截至2022年4月的英文研究、管理指南、荟萃分析和综述文章。

主要发现

  • 复发性心包炎影响15%至30%的初发心包炎患者,首次复发后高达50%的患者有额外复发。
  • 这些患者常进展为秋水仙碱抵抗和皮质类固醇依赖性疾病。
  • 新临床试验和注册数据显示白细胞介素-1阻滞剂在复发性心包炎中有效。
  • 新观察数据支持心脏磁共振成像用于诊断、风险分层和管理。

临床怎么用

  • 在复发性心包炎管理中可考虑心脏磁共振成像用于诊断、风险分层和管理。
  • 对复发性心包炎患者可考虑使用白细胞介素-1阻滞剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Pericarditis is the most common form of pericardial disease. Recurrence of pericarditis affects 15% to 30% of patients after the initial episode of pericarditis. Up to 50% of patients with the first recurrence have additional recurrences. These patients often progress to have colchicine-resistant and corticosteroid-dependent disease. Rapidly evolving cardiac magnetic resonance imaging techniques and novel targeted therapies have paved the way for imaging-guided therapy for recurrent pericarditis. However, the optimal application of these recent advances remains unclear. OBSERVATIONS: A search was conducted using the PubMed and Cochrane databases for English-language studies, management guidelines, meta-analyses, and review articles published until April 2022 on recurrent pericarditis. Following the 2015 European Society of Cardiology guidelines for the diagnosis and management of pericardial diseases, new clinical trials and registry data have emerged that demonstrate the efficacy of interleukin-1 blockers in recurrent pericarditis. In addition, new observational data have come to light supporting the use of cardiac magnetic resonance imaging in the diagnosis, risk stratification, and management of such patients. CONCLUSIONS AND RELEVANCE: Advances in imaging and targeted therapies have led to a paradigm shift in the management of recurrent pericarditis. This narrative review summarizes the established and emerging data on the diagnosis and treatment of recurrent pericarditis with special emphasis on the role of cardiac magnetic resonance imaging and interleukin-1 blockers in the current era of tailored therapy for recurrent pericarditis.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kumar S, Khubber S, Reyaldeen R, et al. Advances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review. JAMA Cardiol. 2022. PMID: 35976625. doi:10.1001/jamacardio.2022.2584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。